Efficacy and safety of monoclonal anti-CD20 antibody (rituximab) for the treatment of patients with recurrent low-grade non-Hodgkin's lymphoma after high-dose chemotherapy and autologous hematopoietic cell transplantation. [electronic resource]
Producer: 20030711Description: 544-9 p. digitalISSN:- 1083-8791
- Adult
- Aged
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Murine-Derived
- Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
- Bone Marrow Transplantation
- Drug Evaluation
- Female
- Hematopoietic Stem Cell Transplantation
- Humans
- Lymphoma, Non-Hodgkin -- drug therapy
- Male
- Middle Aged
- Recurrence
- Remission Induction -- methods
- Retrospective Studies
- Rituximab
- Salvage Therapy
- Transplantation, Autologous
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.